We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 143.00 | 151.00 | 170.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2021 to May 2024
TIDMAMYT
Amryt Pharma plc
Director/PDMR Shareholding
The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Ray Stafford
2
Reason for the notification
a)
Position/status
Chairman
b)
Initial Notification Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Amryt Pharma plc
b)
LEI
213800YNUJEOJ8L4T95
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument,
type of
instrument
Identification code
American Depositary Shares
US03217L1061
b)
Nature of the transaction
Purchase of Shares
c)
Price(s) and volume(s)
Price(s) Volume(s) -------- ----------- $9.40 50,000 ADSs -------- -----------
d)
Aggregated information
-- Aggregated volume
-- Price
N/A -- single transaction
e)
Date of the transaction
November 29, 2021
f)
Place of the transaction
NASDAQ
Contacts Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, ir@amrytpharma.com https://www.globenewswire.com/Tracker?data=W2OZKRCDVu1NafOZ5xeKbf8WNxEcLDj9Ipt5WG0MX6otgDQ5rpXXPIZQABtB5Ns-il8BS6Y1M9m57L-rwBs4GpsSN5kEAHLDSqJdta6niqE= Daniel Bush, Shore Capital, NOMAD, +44 (0) 207 408 4090, amrytcorproate@shorecap.co.uk Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564, tim@lifesciadvisors.com Amber Fennell, Consilium Strategic Communications, +44 (0) 203 709 5700, fennell@consilium-comms.com https://www.globenewswire.com/Tracker?data=JrGWAGqy2CIwnMK60nxPJtp4gbEVcN_lvn9a-bEFJYJ2hH-7h6gkpts5NtDmUerXUgPFWTmXtvwu7oZoTMZHtmCbWEH5XpvQ7BGpFDKvi9H0VGlIwdQaNg9chOlnP5QO
(END) Dow Jones Newswires
November 30, 2021 02:00 ET (07:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Amryt Pharma Chart |
1 Month Amryt Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
